New study targets lung cancer in black patients: can immunotherapy improve outcomes?
NCT ID NCT06745882
First seen Dec 04, 2025 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This phase 2 trial is testing the immunotherapy drug pembrolizumab, given alone or with chemotherapy, in 318 Black patients with advanced non-small cell lung cancer. The goal is to see how well these treatments work in real-world settings and to find biological markers that predict response. Participants must be newly diagnosed and have no certain gene mutations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baptist Clinical Research Institute
RECRUITINGMemphis, Tennessee, 38120, United States
Contact
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
-
Montefiore Medical Cancer Center
RECRUITINGThe Bronx, New York, 10461, United States
Contact
-
TidalHealth Peninsula Regional
RECRUITINGSalisbury, Maryland, 20801, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (immunotherapy) combined with chemotherapy drugs (cisplatin, carboplatin, pemetrexed, abraxane, or paclitaxel)
What this could lead to
If successful, this trial could show that pembrolizumab-based treatment works well for Black patients with advanced lung cancer and help identify who benefits most.
What could go wrong
This is a phase 2 study, not designed for regulatory approval, so results may not change standard care. The small, single-race cohort may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.